Cardiology

1-16 of 294

Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
Cardiology
Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
- Nicholas Marston, MD
Protecting Heart Health in Metastatic Breast Cancer
Protecting Heart Health in Metastatic Breast Cancer
Oncology and Hematology
Protecting Heart Health in Metastatic Breast Cancer
- Ryan Quigley
- Gregory Vidal, MD, PhD
Supporting Patients With ATTR-CM: Preserving Function and Quality of Life
Supporting Patients With ATTR-CM: Preserving Function and Quality of Life
Heart Matters
Supporting Patients With ATTR-CM: Preserving Function and Quality of Life
- Joban Vaishnav, MD
Counseling Patients on Disease Progression in ATTR-CM
Counseling Patients on Disease Progression in ATTR-CM
Heart Matters
Counseling Patients on Disease Progression in ATTR-CM
- Joban Vaishnav, MD
Rethinking Thromboembolic Risk in ATTR-CM Care
Rethinking Thromboembolic Risk in ATTR-CM Care
Heart Matters
Rethinking Thromboembolic Risk in ATTR-CM Care
Silencers and Stabilizers in ATTR-CM: Challenging Assumptions
Silencers and Stabilizers in ATTR-CM: Challenging Assumptions
Heart Matters
Silencers and Stabilizers in ATTR-CM: Challenging Assumptions
Reframing Palliative Care in PAH: Early Integration to Improve Outcomes
Reframing Palliative Care in PAH: Early Integration to Improve Outcomes
Clinician's Roundtable
Reframing Palliative Care in PAH: Early Integration to Improve Outcomes
Targeting Macrophages in Pulmonary Arterial Hypertension
Targeting Macrophages in Pulmonary Arterial Hypertension
Clinician's Roundtable
Targeting Macrophages in Pulmonary Arterial Hypertension
Fatty Acid Profiles May Be Linked to PAH Risk
Fatty Acid Profiles May Be Linked to PAH Risk
AudioAbstracts
Fatty Acid Profiles May Be Linked to PAH Risk
- Ryan Quigley
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Cardiology
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
- Florian Rader, MD
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cardiology
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Joseph Rossano, MD
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Cardiology
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
- Joseph Rossano, MD
Heart Failure Hospitalization and Mortality in Cardiac Amyloidosis
Heart Failure Hospitalization and Mortality in Cardiac Amyloidosis
Heart Matters
Heart Failure Hospitalization and Mortality in Cardiac Amyloidosis
Rebalancing Amyloid in ATTR-CM: Emerging Therapeutic Insights
Rebalancing Amyloid in ATTR-CM: Emerging Therapeutic Insights
AudioAbstracts
Rebalancing Amyloid in ATTR-CM: Emerging Therapeutic Insights
- Hallie Blevins, PhD
AI-Driven Advances in ATTR-CM Care
AI-Driven Advances in ATTR-CM Care
Heart Matters
AI-Driven Advances in ATTR-CM Care
- Frederick Ruberg, MD
Disease-Modifying Advances in ATTR-CM Management
Disease-Modifying Advances in ATTR-CM Management
Heart Matters
Disease-Modifying Advances in ATTR-CM Management

1/6

1-16 of 294

Title

Share on ReachMD

Welcome to Global Cardiology Academy

Welcome to Global
Cardiology Academy